Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears

1 week ago 6

Jonathan Ponciano, The Motley Fool

Tue, December 23, 2025 astatine 11:27 AM CST 5 min read

New York City-based Suvretta Capital Management accrued its MLYS presumption by 387,641 shares successful the 3rd quarter.
The wide presumption worth accrued by $57.25 cardinal from the erstwhile period.
As of September 30, Suvretta reported holding 2.13 cardinal MLYS shares valued astatine $80.85 milion.
These 10 stocks could mint the adjacent question of millionaires ›

On November 14, New York City-based Suvretta Capital Management disclosed a bargain of 387,641 shares of Mineralys Therapeutics (NASDAQ:MLYS) that contributed to an wide presumption summation of astir $57.25 million.

Suvretta Capital Management, a U.S.-based concern adviser, reported successful a November 14 SEC filing that it accrued its involvement successful Mineralys Therapeutics (NASDAQ:MLYS) during the 3rd quarter. The money acquired 387,641 further shares, bringing full holdings to 2.13 cardinal shares worthy $80.85 cardinal arsenic of September 30. The money reported 93 full positions for the quarter.

This bargain brings the fund’s MLYS involvement to 2.07% of 13F AUM aft the third-quarter increase.

Top holdings aft the filing:

NASDAQ:ARQT: $197.51 cardinal (5.99% of AUM)
NASDAQ:BNTC: $138.57 cardinal (4.20% of AUM)
NASDAQ:META: $125.56 cardinal (3.81% of AUM)
NASDAQ:LEGN: $124.51 cardinal (3.77% of AUM)
NASDAQ:ETNB: $121.72 cardinal (3.69% of AUM)

As of Tuesday, shares were priced astatine $36.96, up a staggering 206% and good outperforming the S&P 500, which is up 15% successful the aforesaid period.

Metric

Value

Price (as of Tuesday)	$36.96
Market Capitalization	$2.93 billion
Net Income (TTM)	($171.36 million)
One-Year Price Change	206%

Mineralys Therapeutics' pb merchandise is lorundrostat, an orally administered, highly selective aldosterone synthase inhibitor targeting uncontrolled oregon resistant hypertension.
The institution operates a clinical-stage biopharmaceutical model, generating worth done the research, development, and imaginable commercialization of proprietary therapies for cardiovascular diseases.
Primary customers are expected to see healthcare providers and patients suffering from hypertension, peculiarly those with constricted attraction options.

Mineralys Therapeutics is simply a clinical-stage biotechnology institution focused connected processing innovative therapies for hypertension and related cardiovascular conditions. The company's strategical accent connected lorundrostat positions it to code important unmet needs successful resistant hypertension. With a specialized attack and a proprietary cause candidate, Mineralys aims to found a competitory borderline successful the cardiovascular therapeutics market.